Orexin A-induced enhancement of attentional processing in rats: role of basal forebrain neurons by Zajo, Kristin N. et al.
W&M ScholarWorks 
Arts & Sciences Articles Arts and Sciences 
2016 
Orexin A-induced enhancement of attentional processing in rats: 
role of basal forebrain neurons 
Kristin N. Zajo 
Coll William & Mary, Dept Psychol, Williamsburg, VA 23187 USA 
Joshua A. Burk 
Coll William & Mary, Dept Psychol, Williamsburg, VA 23187 USA 
Jim R. Fadel 
Univ S Carolina, Sch Med, Dept Pharmacol Physiol & Neurosci, Columbia, SC 29208 USA 
Follow this and additional works at: https://scholarworks.wm.edu/aspubs 
Recommended Citation 
Zajo, K. N., Fadel, J. R., & Burk, J. A. (2016). Orexin A-induced enhancement of attentional processing in 
rats: role of basal forebrain neurons. Psychopharmacology, 233(4), 639-647. 
This Article is brought to you for free and open access by the Arts and Sciences at W&M ScholarWorks. It has been 
accepted for inclusion in Arts & Sciences Articles by an authorized administrator of W&M ScholarWorks. For more 
information, please contact scholarworks@wm.edu. 
ORIGINAL INVESTIGATION
Orexin A-induced enhancement of attentional processing in rats:
role of basal forebrain neurons
Kristin N. Zajo1 & Jim R. Fadel2 & Joshua A. Burk1
Received: 27 July 2015 /Accepted: 26 October 2015 /Published online: 4 November 2015
# Springer-Verlag Berlin Heidelberg 2015
Abstract
Rationale Orexins are neuropeptides released in multiple
brain regions from neurons that originate within the lateral
hypothalamus and contiguous perfornical area. The basal fore-
brain, a structure implicated in attentional processing, receives
orexinergic inputs. Our previous work demonstrated that ad-
ministration of an orexin-1 receptor antagonist, SB-334867,
systemically or via infusion directly into the basal forebrain,
can disrupt performance in a task that places explicit demands
on attentional processing.
Objectives Given that the orexin-1 receptor binds orexin A
with high affinity, we tested whether orexin A could enhance
attention in rats.
Methods Attentional performance was assessed using a task
that required discrimination of variable duration visual signals
from trials when no signal was presented. We also tested
whether infusions of orexin A into the lateral ventricle could
attenuate deficits following lesions of medial prefrontal corti-
cal cholinergic projections that arise from the basal forebrain.
Results Infusions of orexin A into the basal forebrain attenu-
ated distracter-induced decreases in attentional performance.
Orexin A attenuated deficits in lesioned animals when a visual
distracter was presented.
Conclusion The present results support the view that orexin A
can enhance attentional performance via actions in the basal
forebrain and may be beneficial for some conditions charac-
terized by attentional dysfunction due to disruption of cortical
cholinergic inputs.
Keywords Acetylcholine . Attention . Basal forebrain .
Hypocretin . Vigilance
Introduction
Since the initial reports of the discovery of orexins (de Lecea
et al. 1998; Sakurai et al. 1998), these neuropeptides have
been associated with numerous processes, including sleep,
hunger, and drug abuse (Mahler et al. 2012; Ritchie et al.
2010; Sakurai et al. 1998; Thannickal et al. 2000). The role
of orexins in attentional processing has also been investigated,
with emphasis on the projections to the basal forebrain
(Arrigoni et al. 2010; Fadel and Burk 2010). Loss of orexin
neurons disrupts acquisition of conditioned orienting re-
sponses (Wheeler et al. 2014). Administration of an orexin-1
receptor antagonist, SB-334867, systemically or directly into
the basal forebrain disrupts attentional performance (Boschen
et al. 2009). These findings have supported the idea that
orexins may be useful for treating cognitive deficits associated
with the disruption of cortical cholinergic projections, such as
in Alzheimer’s disease (Fadel et al. 2013; Fronczek et al.
2012; Slats et al. 2012; Wennstrom et al. 2012).
The orexin-1 receptor has a much higher affinity for bind-
ing orexin A compared with orexin B (Sakurai et al. 1998).
Intranasal or intravenous administration of orexin A can atten-
uate cognitive deficits following sleep deprivation in nonhu-
man primates (Deadwyler et al. 2007). Additionally, orexin A
is thought to play an important role in different forms of learn-
ing and memory (Akbari et al. 2006, 2007; Aou et al. 2003;
Jaeger et al. 2002; Piantadosi et al. 2015; Yang et al. 2013; but
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see also Dietrich and Jenck 2010). Although the evidence is
somewhat mixed, overall, it appears that orexin A can reverse
cognitive deficits under some conditions. However, the neural
mechanisms for these effects of orexin A remain unclear.
Basal forebrain corticopetal cholinergic neurons are known
to be necessary for attentional performance. For example,
immunotoxic lesions of these neurons disrupt signal detection
in several attention-demanding tasks (McGaughy et al. 1996,
2002). Moreover, cortical acetylcholine release is increased
during attention-demanding tasks (Arnold et al. 2002;
Passetti et al. 2000). Using choline-sensitive biosensors, pre-
frontal cortical cholinergic transients are larger on trials with
accurate signal detection following a previous trial when a
response associated with a nonsignal was made (Howe et al.
2013). However, it is unknown whether the basal forebrain is
part of the neural circuitry that mediates any attention-
enhancing effects of orexin A. Moreover, the ability of orexin
A to attenuate attentional deficits associated with damage to
corticopetal cholinergic neurons is not well-studied.
In the present experiments, rats were trained in a two-lever
task that required discrimination of brief, variable visual sig-
nals from trials when no signal was presented (Bushnell et al.
1994; McGaughy and Sarter 1995). This task was selected
because of the sensitivity of the task to manipulations of basal
forebrain corticopetal cholinergic neurons (e.g., McGaughy
et al. 1996, 1999) and because of recent reports that demon-
strated the translational potential and use of this task in mul-
tiple species, including mice (St. Peters et al. 2011) and
humans (Bushnell et al. 2003; Demeter et al. 2008; Howe
et al. 2013). The effects of infusions of orexin A directly into
the basal forebrain were examined in a well-trained version of
the task and with attentional demands increased by presenting
a visual distracter. Given that orexins innervate multiple re-
gions and the clinical interest associated with these neuropep-
tides, in a subsequent experiment, orexin A was infused into
the lateral ventricle prior to attention task performance follow-
ing loss of medial prefrontal cortical cholinergic inputs.
Materials and methods
Subjects
Male FBNF1 hybrid rats, 151–175 g at the beginning of the
experiment were used (National Institute of Aging Colony).
The rats were individually housed in a vivarium which was
temperature and humidity controlled and operated on a
14:10 h light/dark cycle (lights on 0600). All rats were water
restricted throughout the experiment, receiving water during
behavioral testing and for 30 min after each testing session.
Rats were trained 5 to 7 days a week, and received at least 1 h
of water access on days when no behavioral testing occurred.
Food was provided ad libitum throughout the experiment.
Animals were treated in accordance with the guidelines of
the Animal Care and Use Committee at the College of
William & Mary.
Apparatus
Rats were trained in one of the 12 chambers, each located
within a sound attenuating box (Med Associates, Inc.). Each
chamber contained a water port positioned with a dipper that
could be raised to provide water access (0.01-ml tap water).
Two retractable levers were located on either side of the water
port. A panel light was located above each lever and above the
water port. A house light was positioned on the opposite side
of each chamber. Illumination levels of these chambers have
been described (Burk 2004). Behavioral testing programs and
data collection were controlled by a personal computer using
the Med-PC version IV software.
Presurgical attention task training
Training occurred between 9:00 a.m. and 12:00 p.m. daily. In
the initial shaping procedure, rats were trained to press an
extended lever using an FR-1 schedule of reinforcement, with
the rule, to prevent a side bias, that if one lever was pressed
five consecutive times, the other lever had to be pressed to
receive water access. Once animals received 120 rewards in a
session for three sessions, they were moved to the next train-
ing stage, where there were two trial types, signal (1-s
illumination of the central panel light) and nonsignal (no illu-
mination of the central panel light) trials. One second follow-
ing a signal or no signal, the rats were cued to respond by
extension of the levers into the chamber. Rules for training
were counterbalanced, such that half of the rats were rein-
forced (3-s access to 0.01-ml tap water) for pressing the left
lever following a signal, which was recorded as a hit. A miss
was recorded for right lever presses after a signal. For
nonsignal trials, a press of the right lever was considered a
correct rejection and water access was provided, while a press
of the left lever on these trials was recorded as a false alarm.
The rules of the task were reversed for the other half of the rats
such that a right lever press was considered a hit following a
signal presentation whereas the left lever was considered a
correct response on a nonsignal trial. The inter-trial interval
(ITI) was 12 s, and the houselight was illuminated throughout
the session during this stage of training. An incorrect response
during this training phase would be followed by a correction
trial which was the same trial type as that in which the error
occurred. If the rat responded incorrectly for three consecutive
trials, a forced trial occurred in which only the correct lever
was extended into the chamber for 90 s or until the rat
responded. If the errors occurred on signal trials, the central
panel light was illuminated while the lever was extended.
Each session lasted for 45 min, and rats were trained with this
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task until reaching a criterion of >70% accuracy on signal and
nonsignal trials for three consecutive sessions.
After reaching criterion, rats were moved to the final stage
of training prior to surgery. In the final task, the signal dura-
tions (500, 100, 25 ms) and ITI (9±3 s) were shorter and
varied in order to increase explicit attentional demands
(Parasuraman et al. 1987; Koelega et al. 1990). Each training
session was comprised of 162 total trials (81 signal trials, 81
nonsignal trials). For the signal trials, each of the three signal
durations was presented for 27 trials within a session. Trials
were presented in blocks of 18 (9 nonsignal and 9 signal trials,
with 3 of each signal duration), and trial types were selected
randomly without replacement. Rats were considered trained
for surgery when a criterion of >70 % accuracy on trials when
the 500-ms signal was presented and on nonsignal trials for
three consecutive sessions.
Surgical procedures
On the night prior to surgery, rats were provided with
2.7 mg/ml acetaminophen in their drinking water. Rats were
anesthetized via IP injections of 90.0 mg/kg ketamine com-
bined with 9.0 mg/kg xylazine. Once the rats were sufficiently
anesthetized, the surgical area was shaved and rats were posi-
tioned in a stereotaxic device with the incisor bar set at 3.3 mm
below the interaural line. All surgical procedures were con-
ducted under aseptic conditions. In one experiment, rats re-
ceived bilateral implantation of guide cannulae into the basal
forebrain. For these rats, 8-mm guide cannulae (22 gauge)
were implanted at −1.3 mm anterior-posterior (AP) and
±2.7 mmmedial-lateral (ML) from bregma and −4.2 mm from
dura. In a second experiment, rats received infusions of 192
IgG-saporin (0.2 μg/μl; 0.5 μl per site) or saline into the medial
prefrontal cortex (3.7 and 2.6 mm AP, ±0.7 mmML; −3.5 mm
dorsal-ventral (DV); AP and ML from bregma, DV from dura)
and a single guide cannula (hemisphere was randomized across
rats) to allow infusions into the lateral ventricle (−0.8 mm AP,
±1.6 mm ML from bregma; −2.5 mm DV from dura). Three
stainless steel screws and dental cement were also used to se-
cure the cannulae. For rats that received infusions into the me-
dial prefrontal cortex, bone wax was applied above the skull
holes to prevent the dental cement from entering these holes.
Dummy cannulae were inserted to prevent blockage within the
guide cannulae. Following surgery, animals were given a 1-
week recovery period in which food and water were available
ad libitum. Rats were then returned to water restriction and
began to retrain on the attention task.
Postsurgical behavioral testing procedures prior to orexin
A administration
Rats that received bilateral basal forebrain cannulation were
retrained in the same attention task as before surgery. After re-
establishing criterion performance, rats were exposed to two
sham infusion sessions, in which a short (5-mm) internal can-
nula, attached to tubing, was inserted. The rats were then
exposed to a form of the attention task where the houselight
was flashed (1-s on/1-s off) during the middle block of trials
within a testing session (trials 55–108).
Rats that received lateral guide cannula implantation and
infusions of 192 IgG-saporin or saline into the medial prefron-
tal cortex were trained in the same attention task as before
surgery for 15 sessions to establish any baseline effects of
the lesion. Based upon previous findings, no effects of the
lesion were expected on baseline task performance
(Newman and McGaughy 2008). Rats were then exposed to
two sham infusion sessions with the flashing houselight
distracter during the middle block of trials, similar to rats with
bilateral basal forebrain cannulae implantation. After these
sham infusion sessions, all rats were considered ready for
orexin A infusions.
Drug administration procedures
Infusions were made through the insertion of an internal can-
nula attached to a Hamilton syringe by polyethylene tubing. A
total volume of 0.5 μl solution was infused into each cannula
at a rate of 1.0 μl/min. The internal cannula was left in place
for 1 min following the completion of each infusion to allow
for drug diffusion. Animals were then immediately loaded
into the chambers to begin behavioral testing. At least 1 day
of training was allowed between each testing session to re-
establish baseline performance. Orexin A (Tocris, Inc.) was
dissolved in saline and aliquoted into small vials that were
stored at −20° until being used for an infusion. Each vial
was used only once on an infusion day and thus, orexin A
was not repeatedly thawed and frozen. Rats with bilateral
basal forebrain implantation received 0.0 (saline), 0.1, 1.0,
and 10 pM orexin A (Fadel et al. 2005) via internal cannulae
(28 gauge) that extended 3.0 mm beyond the guide cannulae,
with each dose being administered one time prior to task per-
formance in an order that was randomized for each rat. The
infusion procedures for rats receiving intracerebroventricular
infusions were similar, except that the orexin A doses were
increased (0, 10, 100, 1000 pM) via an internal cannula that
extended 1.0 mm beyond the guide cannula. On drug infusion
sessions, rats were tested in a version of the attention task with
the flashing houselight distracter presented during the second
block of trials (trials 55–108) within the session.
Histological procedures and analysis
After being deeply anesthetized via an IP injection of
100.0 mg/kg ketamine and 10.0 mg/kg xylazine, rats were
transcardially perfused with 10 % sucrose followed by 10 %
formalin (for rats with bilateral basal forebrain guide cannulae
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implanted) or 4 % paraformaldehyde (for sham- or 192 IgG-
induced lesions and lateral ventricle guide cannula implanted)
at a pressure of 300 mmHg using a Perfusion One apparatus.
The brains were then removed and placed in the same fixative
for 48 h before being put into a 30 % sucrose solution in
phosphate buffered saline for at least 3 days. The tissue was
then sectioned in 50 μM slices using a freezing microtome.
For rats with bilateral guide cannulae in the basal forebrain,
sections nearest the cannula sites were stained using cresyl
violet and viewed under a microscope to assess cannula place-
ment. For rats with cholinergic lesions or sham lesions, sec-
tions near the medial prefrontal cortex were stained for ace-
tylcholinesterase (AChE)-positive fibers, and cannula location
was also confirmed. AChE histochemistry was performed
using a modification of previous procedures (Tago et al.
1986) and similar to previous work in our laboratory (Burk
et al. 2008). Sections were first rinsed in a 0.1-M phosphate
buffer solution and then incubated in hydrogen peroxide for
20 min. After a rinse in maleate buffer, sections were im-
mersed in a solution composed of 0.5 ml of 0.1 M sodium
citrate, 1.0 ml of 5 mM potassium ferricyanide, 1.0 ml of
30 mM cupric sulfate, 10.0 mg of acetylthiocholine, and
197.5 ml of 0.1 M maleate buffer for 45 min. After rinsing
in 50.0 mM Tris buffer (pH 7.6), sections were incubated for
10 min in the solution prepared using the provided instruc-
tions in a diaminobenzidine (DAB) kit with nickel ammonium
sulfate added. At the end of the incubation period, drops of
0.1 % hydrogen peroxide were added to the sections until
tissue staining was complete. These sections were mounted
on gelatin-coated slides, dehydrated, and then cover slipped.
AChE-positive fibers were quantified in the prelimbic re-
gion of the medial prefrontal cortex as well as the primary
motor (M1) regions in sections from both lesioned and
sham-lesioned animals. AChE-positive fiber density was
quantified using a modified counting grid method (Stichel
and Singer 1987), similar to previous experiments in our lab-
oratory and others (e.g., Burk et al. 2008; McGaughy et al.
1996; McGaughy and Newman 2008). Using an Olympus
BX-51 light microscope with an objective lens magnification
of ×40, three lines that bisected each other at the midpoint
were placed over the image using the Grid Mask function in
ImagePro Discovery. Grid parameters were set to a radius of
400 with segments of 10. Image size was set to 50 %. Each
time a fiber crossed, the lines were counted in at least two
sections in each hemisphere for all animals. The raw values
were averaged together and used to estimate lesion extent.
Behavioral measures and statistical analyses
The number of hits (H), misses (M), correct rejections (CR),
false alarms (FA), and omissions were recorded for each ani-
mal during each testing session. The relative number of hits
[H/(H+M)] and false alarms [FA/(FA+CR)] was calculated.
A sustained attention score (SAT) was then calculated to take
into account accuracy on signal and nonsignal trials in which a
lever press occurred. SAT was calculated using the following
formula: SAT=((H−FA)/ (2×(H+FA)−(H+FA)2) ) (Boschen
et al. 2009;McGaughy et al. 1996). The range of scores for the
SAT measure is from −1 to 1, where a score of 1 indicates
100 % correct responses on signal and nonsignal trials and a
value of 0 indicates an inability to discriminate between signal
and nonsignal trials. To assess accuracy separately on signal
and nonsignal trials, the percentage of hits and correct rejec-
tions were calculated. During orexin A infusion sessions, the
baseline version of the task, with the houselight consistently
illuminated, occurred for the first 54 trials and then, for the
next 54 trials, the houselight was flashed as a distracter. To
determine the effect of the distracter for each rat, for each
measure, the difference between block 1 (standard task with
no distracter) and block 2 (distracter presentation) was calcu-
lated as a distracter score. Positive values indicate greater ac-
curacy during block 1 and that the distracter decreased perfor-
mance. Omissions were analyzed separately frommeasures of
accuracy.
Data were analyzed with mixed factor ANOVAs, which
included factors dose, lesion, and signal duration (where ap-
propriate). Significant interactions were followed up by one-
or two-way ANOVAs followed by t tests. Data were analyzed
with SPSS 19.0 for Windows (SPSS, Chicago, IL, USA). A
level of α=0.05 was used as the criterion for statistical signif-
icance and was adjusted using a modified Bonferroni proce-
dure when multiple t tests were conducted (Keppel 1991).
Results
Effects of orexin A infused bilaterally into the basal
forebrain
A total of ten rats were included in this experiment. Only rats
with appropriate cannulae placements (Fig. 1) and maintained
criterion task performance between infusion sessions (n=6)
were included in these analyses. Intrabasalis orexin A did
not affect performance on the standard task without the
distracter (block 1). A dose (0, 0.1, 1.0, and 10 pM orexin
A) × signal duration (500, 100, and 25 ms) ANOVA for the
SAT measure yielded no significant effects of orexin A during
block 1. Similar analyses were conducted for the relative hits,
as well as for nonsignal trials and omission rates. These anal-
yses also yielded no significant effect of drug dose on any of
these measures during the first block of trials.
Distracter scores were calculated for each rat for each be-
havioral measure to assess the effects of the distracter. This
measure indicated the impairment in performance in response
to the visual distracter presented during block 2, with positive
scores representing a more substantial decrease in attentional
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performance when the distracter was presented. A dose×sig-
nal duration ANOVA did not yield main effects of either fac-
tor, but there was a significant dose×signal duration interac-
tion (F(6,30)=2.866, p<.05, η2=.16) for the difference in
SAT score measure. Follow-up analyses revealed a significant
main effect of dose on trials when the 500-ms signal was
presented (F(3,15)=6.668, p<.05, η2=.57), but not at the
100- or 25-ms signal durations (Fig. 2). This effect was mir-
rored by a dose×signal duration ANOVA for accuracy on
signal trials. For hits, there was not a significant main effect
of either factors, but the analysis did yield a significant dose×
signal duration interaction for the distracter score (F(6,30)=
2.849, p<.05, η2=.19). Separate one-way ANOVAs including
dose as a factor were conducted for each signal duration.
These analyses yielded a main effect of dose at the 500-ms
signal duration (F(3,15)=6.697, p<.05, η2=.57), but not on
the 100- or 25-ms signal trials. Further analyses via paired
sample t tests compared each orexin A dose with vehicle ad-
ministration. Performance following the 10-pM orexin Awas
significantly different compared to vehicle at the longest
(500 ms) signal duration (t(5)=2.711, p<.05, d=1.11). Thus,
at the longest (500 ms) signal duration, the 10-pM orexin A
dose decreased the distracter score for relative hits compared
with vehicle administration. There were no significant effects
of orexin A dose on correct rejections or omissions for the
distracter score. Finally, dose×signal duration ANOVAs for
the SAT measure, relative hits, correct rejections, and omis-
sions on the standard task following the distracter (block 3)
did not yield any significant results.
Histological analyses of rats with medial prefrontal
cortical infusions of 192 IgG-saporin or saline
A total of 19 rats maintained stable performance throughout
drug administration (n=9 sham-lesioned rats and n=10 le-
sioned rats). On average, lesioned animals showed a 60.8 %
loss of AChE-positive fibers in the medial prefrontal cortex
compared to sham-lesioned animals (Fig. 3). To assess wheth-
er the lesions produced a significant decrease in AChE fiber
staining, t tests comparing the mean AChE fiber counts from
Fig. 1 The figure depicts the location of cannula placements for the six
rats that were included in the analyses of attentional task performance (a).
A photomicrograph, taken with a ×2 objective, shows the cannula
placement in one hemisphere of one animal, although all infusions were
bilateral (b). The arrow indicates the infusion site. The section is
approximately −1.3 mm from bregma
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Fig. 2 The figure depicts the difference score (block 1–block 2) when the
distracter was presented compared with the previous block of trials with
no distracter for the SAT measure (a) and a similar difference score for
percent hits (b). The x-axis depicts the orexin doses (n=6)
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the medial PFC andM1 regions were conducted. This analysis
confirmed that lesioned animals showed significantly fewer
AChE fibers in the prelimbic region of the medial prefrontal
cortex compared with sham-lesioned animals (t(17)=10.769,
p<.001, d=10.8; mean±SEMs for AChE-positive fiber
counts: sham-lesioned animals 61.18±3.61, lesioned animals
23.98±1.62) but not in the primary motor cortex (p>.79;
mean±SEMs for AChE-positive fiber counts: sham-lesioned
animals 61.59±2.79, lesioned animals 60.68±2.07).
Performance of lesioned or sham-lesioned rats prior
to orexin A infusions
No significant differences in measures of task performance
were observed between lesioned and sham-lesioned groups
on the 3 days prior to surgery. For the 15 sessions immediately
after surgical recovery, performance was examined averaging
measures from three consecutive sessions (e.g., average of
sessions 1–3 and average of sessions 4–6). For relative hits,
a repeated measures session (five levels)×signal duration
(three levels)×lesion (two conditions) ANOVA did not yield
any effects involving lesion. The lesioned animals did dem-
onstrate a significant decrease in correct rejections compared
to the sham-lesioned animals (F(1,17)=5.962, p< .05,
η2=.26), an effect that was significant during sessions 1–3
(t(17)=2.452, p<.05, d=1.0) and sessions 4–6 (t(17)=2.223,
p<.05, d=.93), but not during subsequent testing sessions
(all p values >.15; Fig. 4). There were no effects involving
lesion on omissions. Thus, immediately after surgery, le-
sioned rats demonstrated a transient decrease in correct
rejections but the performance of this group was not sig-
nificantly different from sham-lesioned animals after 15
postsurgical testing sessions.
Effects of orexin A infusions on attention task
performance of lesioned and sham-lesioned rats
Following drug infusion, animals omitted nearly all trials fol-
lowing the highest orexin dose (1000 pM), rendering the mea-
sures of accuracy difficult to interpret for this dose. Therefore,
measures of accuracy were analyzed only for sessions when
either 0- (vehicle), 10-, or 100-pM orexin Awas administered.
For the SAT measure, a lesion×dose (0, 10, 100 pM orexin
A)×signal duration ANOVA for the first block of trials
yielded a significant lesion×dose×block interaction (F(4,
64)=2.983, p<.05, η2=.17). No other main effects or interac-
tions involving lesion or dose were significant. The basis for
this interaction appeared to be differences at the 25-ms signal
duration; however, follow-up analyses did not reveal any sta-
tistically significant differences between lesioned and sham-
lesioned animals. A similar analysis was conducted for rela-
tive hits, correct rejections, and omissions during block 1 of
trials and yielded no significant effects involving lesion or
dose. The distracter score was calculated for each behavioral
measure similar to those rats that received bilateral infusions
of orexin A into the basal forebrain. For SAT, a lesion×dose
(0, 10, 100 pM orexin A)×signal duration ANOVAyielded a
lesion×dose×signal duration interaction which was ap-
proaching significance (F(4,64)=2.313, p=.067). There were
Fig. 3 The figure shows acetylcholinesterase fiber staining from the
same lesioned animal, in primary motor cortex (a) or in the prelimbic
region of the medial prefrontal cortex (b)
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animals. The y-axis depicts percent correct rejections
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no significant main effects or other interactions including le-
sion or dose. For relative hits, a lesion×dose×signal duration,
revealed a significant lesion×dose×signal duration interac-
tion (F(4,68)=2.656, p<.05, η2=.14) for the distracter score,
but no main effects or other interactions involving lesion or
dose. This interaction was further assessed by conducting sep-
arate dose×lesion ANOVAs at each signal duration. For rela-
tive hits, there was a significant dose×lesion interaction (F(2,
34)=4.965, p<.05, η2=.21), but no significant main effects, at
the 25-ms signal duration, but not on 500- or 100-ms signal
trials. This dose×lesion interaction was further assessed with
separate one-way ANOVAs for dose for sham-lesioned and
lesioned animals on 25-ms signal trials. No significant effects
of dose were observed for the sham-lesioned animals (p>.50).
There was, however, a significant main effect of dose on ac-
curacy at the 25-ms signal duration for the lesioned group
(F(2,18)=6.922, p<.05, η2=.43). To clarify the nature of this
effect, paired sample t tests comparing each orexin A dose
with vehicle administration were conducted for the lesioned
animals. These analyses yielded a significant difference in the
distracter scores when vehicle administration was compared
with 100 pM orexin A (t(9)=2.973, p<.05, d=.94). Thus, at
the 25-ms signal duration, the 100-pM orexin A dose de-
creased the distracter score for relative hits compared with
vehicle administration, indicating that the lateral ventricle in-
fusions of 100 pM orexin A may reduce distractibility at the
25-ms level (Fig. 5). There were no significant effects of
orexin A dose on correct rejections or omissions for the
distracter score. Finally, lesion×dose×signal duration
ANOVAs for the SAT measure and relative hits as well as
lesion×dose ANOVAs for correct rejections and omissions
on the standard task following the distracter (block 3) did
not yield any significant effects involving dose or lesion.
Discussion
The present experiments tested whether orexin A could en-
hance attentional performance via direct infusions into the
basal forebrain and, in a separate experiment, via intraventric-
ular infusion following sham- or 192 IgG-saporin-induced
lesions of cholinergic projections to the medial prefrontal cor-
tex. The present results extend previous findings by showing
that attention-demanding aspects of task performance benefit
the most from orexin A and by demonstrating that changes in
attentional performance following loss of medial prefrontal
cortex cholinergic inputs can be attenuated by orexin A.
In both experiments, beneficial effects of orexin A on at-
tentional performance were observed when a visual distracter
was presented. Thus, orexin A does not appear to enhance
performance in a well-trained version of the task, but rather
when attentional demands are augmented by a visual
distracter. Moreover, the benefits of orexin A were not ob-
served during the final block of trials, when subjects are re-
covering from the effects of the distracter. The orexin A-
induced performance enhancement specifically during the
distracter condition suggests that the drug effects were not
some general increase in arousal that improved all aspects of
the task or specific facilitation of motivation. This conclusion
is further supported by a lack of effect of orexin A on
omissions.
Selective lesions of basal forebrain corticopetal cholinergic
neurons typically decrease signal detection in this task (e.g.,
McGaughy et al. 1996, 1999). In the present study, the bene-
ficial effects of orexin A were primarily observed on signal
trials. These results potentially support the conclusion that the
beneficial effects of orexin A are mediated via corticopetal
cholinergic inputs. However, caution should be taken with this
interpretation because orexins are also released onto basal
forebrain noncholinergic neurons. The role of basal forebrain
noncholinergic neurons in attention, and their interactions
with cholinergic neurons, remains poorly understood (Sarter
and Bruno 2002). Additionally, the obvious possibility exists
that icv orexin A administration led to beneficial effects by
actions outside of basal forebrain corticopetal neurons (Peyron
et al. 1998). Lambe et al. (2005), for example, have demon-
strated a pro-attentional effect of orexins mediated by orexin-2
receptors on thalamo-prefrontal projections.
When infused into the basal forebrain, orexin A increased
the decline in performance on trials when the 500-ms signal
was presented. Interestingly, this corresponds well with our
previous work, showing that orexin-1 receptor blockade de-
creases accuracy on trials with a longer signal duration
(Boschen et al. 2009). We previously suggested that this pat-
tern of deficits reflected disrupted processing of the task rules
for signal trials rather than signal perception. If rule processing
is affected, then the change in performance would be predicted
to occur following the longest signal, because this is the signal
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Fig. 5 The figure depicts the difference score (block 1–block 2) when the
distracter was presented compared with the previous block of trials with
no distracter for percent hits on trials when the 25-ms signal was
presented for sham-lesioned (n=9) and for 192 IgG-saporin-induced
lesioned animals (n=10). The x-axis depicts the orexin doses
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that the subject is most likely to detect. Collectively, we see
that orexin receptor blockade and orexin A administration
bidirectionally affect accuracy on 500-ms signal trials, al-
though we did not find that orexin receptor blockade selec-
tively affected accuracy on trials with a distracter (Boschen
et al. 2009). The receptors responsible for the effects of orexin
A require further investigation. Orexin A binds to both orexin-
1 and orexin-2 receptors (Sakurai et al. 1998), and these re-
ceptors are expressed at similar levels in the basal forebrain
(Marcus et al. 2001). The present effects of orexin A could be
due to actions at orexin-1 or orexin-2 receptors or activation of
both of these receptor subtypes.
Lesions of the cholinergic projections to the medial pre-
frontal cortex transiently decreased correct rejections. It is
somewhat surprising that the lesions affected accuracy on
nonsignal, rather than signal trials, but the difference in per-
formance supports that the lesions were effective. The extent
of lesions was similar to previous studies in which this
immunotoxin was infused into the medial prefrontal cortex
(Newman and McGaughy 2008). As expected, the lesioned
and sham-lesioned animals’ performance did not differ during
the final sessions prior to orexin A administration. Lesioned
animals demonstrated improvement in detecting the 25-ms
signal following the 100-pM orexin A compared with vehicle
administration when the distracter was presented. The 25-ms
signal may be considered the most challenging to detect.
Thus, the beneficial effects of orexin A for lesioned animals’
performance are prominent during the highest attentional de-
mands, both in terms of increased background noise and sig-
nal duration. The beneficial effects of intraventricular orexin
A in lesioned animals does improve accuracy at a shorter
signal duration compared to the effects of orexin A infused
into the basal forebrain. It is certainly possible that, with these
different methods of administration, in lesioned versus intact
animals, orexin A is providing beneficial effects through dif-
ferent neural mechanisms. Further investigation of the neural
basis of the beneficial effects of intraventricular orexin A is
needed.
These results add to the growing literature about the bene-
ficial cognitive effects of orexin A (Piantadosi et al. 2015).
The basal forebrain appears to be one brain structure that
mediates some of the effects of orexin A on attention.
Collectively, these findings support the conclusion that orexin
A is a fruitful target for future research into treatments for
disorders characterized by attentional deficits.
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